

ORASURE TECHNOLOGIES INC

Form 8-K

December 22, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

---

### CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 22, 2004

---

## OraSure Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**001-16537**  
(Commission File Number)

**36-4370966**  
(I.R.S. Employer

Identification No.)

**220 East First Street**

**Bethlehem, Pennsylvania**  
(Address of Principal Executive Offices)

**18015-1360**  
(Zip Code)

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

Registrant's telephone number, including area code: 610-882-1820

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure**

On December 22, 2004, OraSure Technologies, Inc. (the Company) issued a press release (i) announcing that The Centers for Disease Control and Prevention will purchase approximately \$2.3 million of the Company's OraQuic®ADVANCE Rapid HIV-1/2 Antibody Tests, and (ii) updating the Company's financial guidance for 2005. A copy of the press release is attached as Exhibit 99 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

**(c) Exhibits**

**Exhibit**

<u>Number</u>	<u>Description</u>
99	Press Release dated December 22, 2004, (i) announcing that The Centers for Disease Control and Prevention will purchase approximately \$2.3 million of the Company's OraQuic®ADVANCE Rapid HIV-1/2 Antibody Tests, and (ii) updating the Company's financial guidance for 2005.

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: December 22, 2004

By: /s/ Jack E. Jerrett

---

Jack E. Jerrett  
Senior Vice President, General Counsel  
and Secretary

Index to Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99	Press Release dated December 22, 2004, (i) announcing that The Centers for Disease Control and Prevention will purchase approximately \$2.3 million of the Company's OraQuic® <i>ADVANCE</i> Rapid HIV-1/2 Antibody Tests, and (ii) updating the Company's financial guidance for 2005.